Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy

BACKGROUND: Young age at breast cancer (BC) diagnosis has historically been a rationale for overtreatment. Limited data with short follow-up exist on the prognostic value of age at diagnosis in HER2-positive BC and the benefit of anti-HER2 therapy in young patients. METHODS: APHINITY (NCT01358877) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambertini, Matteo, Fielding, Shona, Loibl, Sibylle, Janni, Wolfgang, Clark, Emma, Franzoi, Maria Alice, Fumagalli, Debora, Caballero, Carmela, Arecco, Luca, Salomoni, Sharon, Ponde, Noam F, Poggio, Francesca, Kim, Hee Jeong, Villarreal-Garza, Cynthia, Pagani, Olivia, Paluch-Shimon, Shani, Ballestrero, Alberto, Del Mastro, Lucia, Piccart, Martine, Bines, Jose, Partridge, Ann H, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360461/
https://www.ncbi.nlm.nih.gov/pubmed/35512402
http://dx.doi.org/10.1093/jnci/djac096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360461/
https://www.ncbi.nlm.nih.gov/pubmed/35512402
http://dx.doi.org/10.1093/jnci/djac096

Ejemplares similares